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Progression of idiopathic dilated cardiomyopathy (IDCM) is marked with extensive left ventricular remodeling whose clinical
manifestations andmolecular basis are poorly understood.We aimed to evaluate the clinical potential of titin ligands inmonitoring
progression of cardiac remodeling associated with end-stage IDCM. Expression patterns of 8 mechanoptotic machinery-associated
titin ligands (ANKRD1, ANKRD2, TRIM63, TRIM55, NBR1,MLP, FHL2, and TCAP) were quantitated in endomyocardial biopsies
from 25 patients with advanced IDCM. When comparing NYHA disease stages, elevated ANKRD1 expression levels marked
transition from NYHA < IV to NYHA IV. ANKRD1 expression levels closely correlated with systolic strain depression and short
E wave deceleration time, as determined by echocardiography. On molecular level, myocardial ANKRD1 and serum adiponectin
correlated with low BAX/BCL-2 ratios, indicative of antiapoptotic tissue propensity observed during the worsening of heart failure.
ANKRD1 is a potential marker for cardiac remodeling and disease progression in IDCM. ANKRD1 expression correlated with
reduced cardiac contractility and compliance. The association of ANKRD1 with antiapoptotic response suggests its role as myocyte
survival factor during late stage heart disease, warranting further studies on ANKRD1 during end-stage heart failure.
1. Introduction
Despite intensive search for therapeutic interventions, idio-
pathic dilated cardiomyopathy (IDCM) remains the major
cause of heart failure eventually leading to heart trans-
plantation. Limited availability of donor hearts results in
long waiting times before transplantation can be performed.
Many patients with end-stage heart failure perish before
a donor heart becomes available. Management of patients
awaiting transplantation is demanding, because some of
them remain stable while others deteriorate quickly [1].
However, transplantation specialists do not have reliable tools
to differentiate between these two disease courses. Therefore,
there is a pressing need for markers predicting the prognosis
and disease course of end-stage heart failure caused by IDCM
in order to prioritize patient listing for transplantation.
Myocyte apoptosis was shown to be a contributor to the
development of heart failure (HF) [2], whereas experimental
studies on mouse models have suggested that this process
might at least be mediated trough the titin filament and its
ligands [3]. However, this hypothesis has not been tested so
far in clinical settings. Here, we have evaluated expression
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levels of 8 titin ligands in endomyocardial biopsies (EMB).
Differences in ANKRD1 expression pattern were found to
be most informative: ANKRD1 levels were associated with
decreased cardiac contractility and compliance. ANKRD1
gene encodes an ankyrin repeat-domain containing pro-
tein 1 (Ankrd1, known as well as CARP-cardiac ankyrin
repeat protein). Ankrd1 belongs to a family muscle ankyrin
repeat proteins, interacting with titin in a stretch-dependent
manner: upon mechanical stretch it translocates to the
nucleus, where it acts as transcription cofactor [4]. Ven-
tricular ANKRD1 upregulation was observed in increased
stretch states such as experimental pressure overload [5] or
clinical heart failure due to dilated [6] and arrhythmogenic
right ventricular cardiomyopathy [7]. Moreover, mutations
in ANKRD1 were found to be associated with dilated [8]
and hypertrophic cardiomyopathy [9]. Functionally, myocar-
dial ANKRD1 acts as an antiapoptotic survival factor after
ischemia-reperfusion injury [10] and hypoxia [11] and is
downregulated in apoptosis-driven [12, 13] anthracycline
cardiomyopathy [14]. In this work, we present data indi-
cating that ANKRD1 together with adiponectin might act
as myocyte survival factors, associated with antiapoptotic
response in the terminal stage of IDCM.
2. Materials and Methods
2.1. Patients. Our study cohort was composed of patients
admitted to the Vilnius University Hospital during 2011–2013
with suspected diagnosis of IDCM. All patients underwent
a careful history and physical examination, as well as rou-
tine laboratory studies, including B-type natriuretic peptide
(BNP), adiponectin, and cardiac troponin T (hsTnT). 23
patients were selected because of a reduced left ventricular
ejection fraction (LVEF < 45%) in the absence of significant
coronary artery disease (stenosis of coronary arteries of less
than 50%), a history of myocardial infarction, and other
specific heartmuscle diseases (primary valvular heart disease,
toxic cardiomyopathy, arterial hypertension, renal failure,
and abuse of alcohol or illicit drugs), all consistent with
primary IDCM. IDCM diagnosis was confirmed by histo-
logical analysis of endomyocardial biopsies (EMB). Patients
who were diagnosed as having acute myocarditis according
to histological evidence were excluded from the present
study. NYHA class was assigned by a clinician unaware of
patient echocardiographic investigation. All patients received
maximal pharmacological heart failure therapy according to
European Society of Cardiology guidelines: ACE inhibitors
or angiotensin receptors blockers, 𝛽-blockers, mineralocorti-
coid receptors blockers, digitalis (in case of atrial fibrillation),
diuretics, anticoagulant (in case of atrial fibrillation, EF
< 40%), and antiarrhythmics (class III: amiodarone) (see
Supplementary Table 1 in Supplementary Material avail-
able online at http://dx.doi.org/10.1155/2015/273936). Clinical
decision about possible treatment with cardiac resynchro-
nization therapy, radiofrequency ablation, or implantation of
a left ventricular assist device or implantable cardioverter-
defibrillator was made after coronary angiography and EMB.
All patients gave written informed consent to this study,
including cardiac catheterisation and EMB. The study was
approved by Lithuanian Bioethics Committee (Protocol
number 158200-2011/09) and conducted in compliance with
the Declaration of Helsinki.
2.2. Echocardiography and Cardiac Catheterisation. Echocar-
diographic evaluation was performed 1 day before cardiac
catheterisation by GE Vivid 7 and 9 ultrasound system by an
investigator blinded for the study objectives.The standard LV
apical (apical 4, apical 2, and apical 3) views and parasternal
short axis views at mid-papillary level were acquired at
70–90 frames/s. Conventional echocardiographic parameters
such as left ventricular ejection fraction (LVEF), left ven-
tricular end-diastolic dimension (LVEDD), left ventricular
end-systolic dimension (LVESD), velocities of E and A waves
(E and A) and their ratio (E/A), and E deceleration time
(DcT) were obtained. All images were stored digitally for
subsequent offline analysis. Quantification of myocardial
deformation values was performed by 2D speckle tracking
using Echopac PCBT08 (GE Healthcare) software. After
the manual selection, speckles were assumed automatically
and then confirmed by the investigator. By the semiauto-
matic postprocessing longitudinal (in 4 chamber-4C, two-
chamber-2C, and three chamber-3C views), circumferential,
and radial strain (RS) and strain rate parameters were
extracted. Mean pulmonary artery (PA) pressure, pulmonary
capillary wedge pressure (PCWP), and pulmonary vascular
resistance (PVR) were measured and EMB was taken during
right heart catheterization. Biopsy specimens were immedi-
ately placed to −70∘C until further processing.
2.3. Quantitative RT-PCR. RNA from EMB samples was
extracted using RNeasy fibrous tissue minikit according to
provided protocol (Qiagen). Tissue was directly homoge-
nized in lysis buffer using Ultra-Turrax device. RNA was
reverse transcribed using High Capacity RNA-to-cDNA
Kit primed with mixture of random and poly-dT primers
(Invitrogen). Transcripts were quantified using TaqMan
Gene Expression assay on Real-Time Stratagene MX 3005P
machine following manufacturer recommendations. Ampli-
fication efficiency validated TaqMan probes (Supplementary
Table 2) used in this work are presented in Table 2. 18S rRNA
was used for standardization. As this study did not contain a
reference group and was based on individual EMB samples,
𝐶
𝑡
method could not be used for quantification of transcript
levels. Therefore relative transcript abundances were quanti-
fied using𝐶
𝑡
method (𝐶
𝑡 gene of interest−𝐶𝑡 S18 rRNA). Transcript
levels in this work are expressed as negative 𝐶
𝑡
values;
thus higher −𝐶
𝑡
values denote higher mRNA levels whereas
negative 𝐶
𝑡
values represent genes that are less abundant
compared with the reference gene. Bax/Bcl-2 ratios were
calculated as 𝐶
𝑡
((𝐶
𝑡 Bax −𝐶𝑡 S18 rRNA) − (𝐶𝑡 Bcl-2 −𝐶𝑡 S18 rRNA))
corresponding to relative expression ratio [15].
2.4. Measurement of Activated Caspase-3. Levels of activated
caspase-3 in EMB samples were determined using ELISA,
specific for the activated protein form (Invitrogen, Paisley,
UK). Tissue samples were lysed by sonification in RIPA
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Table 1: Patient characteristics.
NYHA class
<IV IV
Age (years) 44.2 ± 14.2 43.5 ± 13.9
Sex
Female 4 1
Male 15 5
BMI (kg/m2) 24.7 ± 4.7 28.7 ± 5.1
NYHA class
II 1
III 16
III-IV 2
IV 6
BNP (pg/mL) 1259 ± 1180 1964 ± 1177
TnT (pg/mL) 80.9 ± 143.5 34.4 ± 13.9
Adiponectin (𝜇g/mL) 22.9 ± 12.6 33.8 ± 17.5
LVEF (%) 24.1 ± 7.4 20.1 ± 6.2
LVESD (mm) 58.2 ± 9.9 64.3 ± 10.2
LVEDD (mm) 67.3 ± 7.4 71.1 ± 12
RAP (mmHg) 12.5 ± 7.3 16.2 ± 11
PAP (mmHg) 32.2 ± 12.1 43.2 ± 15.8
PCWP (mmHg) 23 ± 9.1 31.8 ± 14.2
PVR (Wood units) 2.5 ± 1.7 3.2 ± 0.8
E wave (m/s) 0.9 ± 0.2 1 ± 0.3
A wave (m/s) 0.5 ± 0.2 0.4 ± 0.1
E/A 1.8 ± 1.1 2.3 ± 0.4
E wave 𝑇dec (ms) 140.1 ± 35.2 109 ± 45.4
lysis buffer (Thermo Scientific Inc., USA) supplemented with
phosphatase and protease inhibitors according to manufac-
turer’s recommendations (Thermo Scientific Inc., USA). Pro-
tein content in clarified lysates was measured using modified
Lowry protein assay using bovine serum albumin as standard
according to the provided protocol (Thermo Scientific Inc.,
USA). Analyte concentration was expressed as ng/mg of total
protein.
2.5. Statistics. Statistical analysis was performed using SPSS
17 software. Nonparametric Mann-Whitney 𝑈 test was used
to assess differences between two independent groups. Pear-
son product-moment correlation coefficient was used to
evaluate linear dependence between values. If otherwise not
indicated, a value of 𝑃 < 0.05 was taken as significant (two-
tailed).
3. Results
3.1. Induction of the Titin Ligands ANKRD1, ANKRD2, and
TRIM63 in Patients with End-Stage IDCM in Correlation
with NYHA Staging. Here, we determined the transcript
levels of ANKRD1, ANKRD2, TRIM63, TRIM55, NBR1, MLP,
FHL2, and TCAP in EMB biopsies from end-stage IDCM
patient cohort to test their potential roles in titin-based
cellular stress transmission. Clinically, we surveyed patients
with significantly reduced LVEF, elevated BNP and TnT val-
ues, elevated intracardiac pressures, and impaired relaxation
(Table 1). Patients were divided into two groups according
to the severity of HF symptoms based on NYHA functional
Table 2: Differences in myocardial expression patterns of titin
ligands according to NYHA functional class <IV (𝑛 = 19) and
NYHA IV (𝑛 = 6).
Transcript
level (−Δ𝐶
𝑡
)
NYHA class
𝑃 value
<IV IV
𝐴𝑁𝐾𝑅𝐷1
∗
−9.42 ± 0.7 −6.83 ± 0.7 0.01
𝐴𝑁𝐾𝑅𝐷2
∗
−16.79 ± 0.7 −14.5 ± 0.8 0.03
𝑇𝑅𝐼𝑀63
∗
−13.81 ± 0.6 −11.82 ± 0.5 0.03
𝑇𝑅𝐼𝑀55 −14.23 ± 0.8 −13.11 ± 0.7 0.25
𝑁𝐵𝑅1 −11.97 ± 0.7 −11.73 ± 0.9 0.44
𝑀𝐿𝑃 −10.39 ± 1.0 −9.15 ± 0.9 0.20
𝐹𝐻𝐿2 −10.07 ± 0.8 −9.75 ± 0.6 0.56
𝑇𝐶𝐴𝑃 −7.08 ± 0.9 −6.16 ± 0.8 0.30
BCL-2∗ −17.81 ± 0.4 −16.25 ± 0.7 0.02
𝐵𝐴𝑋 −15.71 ± 0.3 −14.39 ± 0.9 0.22
Significant differences (𝑃 value < 0.05 of the Mann-Whitney𝑈 test) marked
with ∗.
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Figure 1: Myocardial titin ligand expression patterns associate with
disease progression in IDCM patients. Statistically significant titin
ligand expression differences represented as bar graph. Data are
presented as mean ± 2 s.e.m. Note the highest expression level
and the most pronounced difference between groups in ANKRD1
expression pattern.
class: Group IV (symptomatically Severe HF) and Group <IV
(mainly class III; symptomatically moderate HF), and the
expression levels ofmechanoptoticmachinerymembers were
compared (Table 2). Out of 8 studied transcripts, ANKRD1,
ANKRD2, and TRIM63 were significantly higher in NYHA
class IV than <IV NYHA class group (Figure 1, 𝑃 = 0.01 for
ANKRD1 and 𝑃 = 0.03 for ANKRD2 and TRIM63). ANKRD1
had the highest expression levels compared to other titin
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Figure 2: Increased ANKRD1 expression marks left ventricular remodeling. (a) Linear correlation between ANKRD1 expression and radial
stain. Regression line is represented within 95% confidence interval for the mean value. A negative correlation between ANKRD1 expression
(−𝐶
𝑡
) and radial strain (RS; %) was found (𝑛 = 14, 𝑟 = −0.54, 𝑃 < 0.05). (b) Linear correlation between ANKRD1 expression and E wave
deceleration time. Regression line is represented within 95% confidence interval for the mean value. A negative correlation betweenANKRD1
expression (−𝐶
𝑡
) and E wave deceleration time (ms) was detected (𝑛 = 21, 𝑟 = −0.495, 𝑃 < 0.05).
ligands and themost profound 6-fold induction (calculated as
2
𝐶
𝑡
IV NYHA−𝐶
𝑡
<IV NYHA) in NYHA IV patients as compared to
NYHA <IV patients. Therefore, ANKRD1 expression pattern
was the most sensitive to the disease progression and was
chosen for the further analysis.
3.2. ANKRD1 Expression Correlates with LV Remodeling in
End-Stage IDCM Patients. In order to investigate clinical
correlates of ANKRD1 expression we looked for further
clinical parameters different between NYHA class >IV and
<IV. Statistically significant differences between NYHA <IV
and NYHA IV groups were only detected for parameters
of systolic strain (Table 3). Strain measurements quantify
magnitudes and velocities of myocardial deformation esti-
mating myocardial contractility [16]. Radial and longitudinal
strain in 3C projection showed marked reduction in severe
HF patients (NYHA IV) when compared to symptomati-
cally moderate HF patients (NYHA <IV) (Table 3). Corre-
lation analysis confirmed that reduced cardiac contractility
correlated with ANKRD1 expression independently from
NYHA functional class (Figure 2(a)). Further, we found that
ANKRD1 expression correlated with the E wave deceleration
time shortening, which is an index for LV stiffness [17]
(Figure 2(b)). Taken together, ANKRD1 expression is asso-
ciated with LV remodeling resulting in reduced cardiac
contractility and compliance.
3.3. Deteriorating Cardiac Contractility Is Associated with
Blunted Myocardial Vulnerability to Apoptosis. Because
myocyte apoptosis is associated with contractile dysfunction
in HF [18, 19] and ANKRD1 acts as antiapoptotic [10, 11],
we hypothesized that decreased cardiac contractility in
end-stage IDCM patients is associated with proteins
Table 3: Differences in strain parameters between NYHA <IV and
NYHA IV groups.
Strain parameter NYHA class 𝑃 value
<IV IV
4C strain (%) −7.4 ± 1 −4 ± 0.8 0.10
4C strain rate (s−1) −0.4 ± 0 −0.2 ± 0 0.10
2C strain (%) −6.7 ± 0.9 −5.1 ± 0.9 0.25
2C strain rate (s−1) −0.3 ± 0 −0.3 ± 0 0.34
3C strain (%)∗ −8.1 ± 0.8 −3.9 ± 1.1 0.01
3C strain rate (s−1) −0.8 ± 0.4 −0.2 ± 0 0.11
Circumferential strain (%) −5.5 ± 0.5 −4.3 ± 1.2 0.51
Circumferential strain rate (s−1) −0.4 ± 0 −0.2 ± 0 0.20
Radial strain (%)∗ 17.4 ± 2.3 6.1 ± 1.7 0.01
Radial strain rate (s−1) 1.3 ± 0.1 0.8 ± 0.2 0.11
Note further reduction of systolic strain parameters along disease progres-
sion.
Significant differences (𝑃 value < 0.05 of the Mann-Whitney U test) marked
with ∗.
involved in mechanoptosis. As presented above, the most
pronounced deterioration of cardiac contractility upon
IDCM progression was observed in radial direction by
echocardiography, referred to as radial strain (RS). Thus, for
further analysis we used RS to monitor worsening of cardiac
contractility. Patients were subdivided into two groups
according to the median value of RS. The above median RS
group displayed normal radial cardiac contractility as mean
RS was still within a healthy population reference range
[20]. In contrast, patients with RS values below the median
RS had severely impaired cardiac contractility (Table 4).
Further strain parameters, RS rate and 3C longitudinal
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Table 4: Clinical characteristics of patients (𝑛 = 14) with high radial
strain (RS, above median) and low RS (below median).
Radial strain
Below median Above median
Age (years) 48 ± 6.51 44 ± 3.3
Sex
Female 2 3
Male 5 4
BMI (kg/m2) 25.6 ± 2.0 27.03 ± 2.13
NYHA class
III 3 5
III-IV 0 2
IV 4 0
BNP (pg/mL)∗ 1824 ± 461 525 ± 197
TnT (pg/mL) 31.17 ± 6.1 157 ± 136.4
Adiponectin (𝜇g/mL)∗ 35 ± 5.4 8.5 ± 1.8
LVEF (%) 21.29 ± 1.1 25.29 ± 3.34
LVESD (mm) 61 ± 2.1 55.5 ± 2.1
LVEDD (mm) 71.3 ± 2.1 65.6 ± 1.7
RAP (mmHg) 12.33 ± 3.9 9.33 ± 1.28
PAP (mmHg) 32.6 ± 4.7 25.3 ± 1.91
PCWP (mmHg) 23.14 ± 3.8 18.17 ± 1.51
PVR (Wood units) 2.5 ± 0.44 2.025 ± 0.55
E wave (m/s) 1 ± 0.11 0.92 ± 0.06
A wave (m/s) 0.398 ± 0.05 0.63 ± 0.095
E/A 2.71 ± 0.36 1.86 ± 0.48
E wave 𝑇dec (ms) 118 ± 12 146 ± 15.42
3C strain (%)∗ −5.07 ± 0.96 −8.75 ± 0.98
Radial strain (%)∗ 7.39 ± 1.23 21.1 ± 1.95
Radial strain rate (s−1)∗ 0.88 ± 0.19 1.55 ± 0.13
ANKRD1 (−Δ𝐶
𝑡
)
∗
−7.02 ± 1.1 −10.26 ± 0.68
BCL-2 (−Δ𝐶
𝑡
)† −16.36 ± 1.0 −18.67 ± 0.22
BAX (−Δ𝐶
𝑡
) −14.60 ± 1.0 −16.02 ± 0.17
BAX/BCL-2 ratio (ΔΔ𝐶
𝑡
)
∗ 1.76 ± 0.27 2.65 ± 0.19
Active caspase-3 (ng/mg)† 0.19 ± 0.06 0.45 ± 0.11
∗
𝑃two-sided < 0.05;
†
𝑃one-sided < 0.05 (Mann-Whitney 𝑈 test).
strain, indicated better cardiac contractility in above median
RS group. None of the echocardiographic parameters
or cardiac chamber pressure values reached statistically
significant differences. However, the group with severe
loss of radial deformation (below RS median) showed a
tendency towards worse cardiac function. ANKRD1 and
stretch-marker BNP levels were higher in the group with
impaired radial contractility. Next, we evaluated transcript
levels of proapoptotic BAX and antiapoptotic BCL-2 whose
ratio defines tissue propensity to apoptosis [21] and amount
of active caspase-3, a major apoptosis executer [22] that
corresponds to intensity of ongoing apoptosis. Better
contractility correlated with lower antiapoptotic BCL-2 levels
and thus corresponded to a group more prone to apoptosis
(Figures 3(a) and 3(b)). Consequently, higher levels of
ongoing apoptosis, as measured by levels of active caspase-
3, were detected in higher RS group (Figure 3(c)). Low
BAX/BCL-2 ratios and therefore myocardial insensitivity
to apoptosis correlated well with ANKRD1 transcript levels
(Figure 4(a)). In addition, BAX/BCL-2 ratios inversely
correlated with serum adiponectin levels (Figure 4(b)).
Taken together our data imply that ANKRD1 might be
involved in antiapoptotic response observed in end-stage
DCM [23].
4. Discussion
Genes coding for titin binding proteins has been suggested
to act as members of a titin filament based stress sensing
mechanoptotic machinery in previous mouse work [3]. Here,
we tested for a potential clinical significance of titin ligands
for LV remodeling in IDCM patients. Out of 8 studied
transcripts we found that ANKRD1 expression levels showed
the most significant increase in symptomatically severe HF
(NYHA class IV) compared to moderate HF (NYHA < IV)
patients. Clinically, severe HF patients had notably poorer
systolic strain rates indicating reduced cardiac contractility.
Our data indicate that myocardial strain parameters are
superior to LV ejection fraction and chamber diameter,
intracardiac pressure, and relaxation measures in detecting
the severity of heart failure as estimated by NYHA functional
class. Our findings are in line with previous studies where
myocardial strain predicted rapid HF progression in end-
stage IDCM patients [1]. We found a significant reduction of
longitudinal strain in 4C and 3C projections, but the major
difference was observed for radial strain measurements.
These findings are in line with a study on hypertensive
patients with heart failure, where a reduction in radial strain
was only seen in NYHA classes III-IV, whereas longitudi-
nal strain was decreased as early as NYHA class II [24].
Moreover we found that ANKRD1 expression correlated not
only with reduced LV contractility, but also with increased
cardiac stiffness; ANKRD1 expression positively correlated
with shortening of E wave deceleration time, marking
restrictive filling pattern—the most powerful independent
prognostic indicator of poor outcome or transplantation in
DCMpatients [25]. Taken together our data indicate that ven-
tricularANKRD1 levels in IDCM patients are associated with
progression of LV remodeling, resulting in reduced cardiac
contractility and compliance. In DCM, myocyte apoptosis is
related to LV dysfunction [26] and appears to directly affect
cardiac contractility [18, 19]. Finally, myocardial ANKRD1
functions as an antiapoptotic survival factor after ischemia-
reperfusion injury [10] and hypoxia [11]. Therefore, we
investigated the relation between ANKRD1 expression and
apoptotic status in the myocardium. We found that tissue
samples more susceptible to apoptosis (high BAX/BCL-2
ratio) had lower ANKRD1 levels than apoptosis-resistant
samples (lowBAX/BCL-2 ratio) implying thatANKRD1 could
act as myocyte survival factor. However, counterintuitively
the group with less impaired cardiac contractility (above
median RS) was more prone to apoptosis than low RS
group. In addition, impaired contractility was associated with
higherBAX/BCL-2 ratios and elevated levels of key apoptosis-
executing enzyme [22] and active caspase-3, indicating that
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Figure 3: ANKRD1 and adiponectin upregulation are associated with antiapoptotic response in progression of IDCM. (a) Difference in
BAX/BCL-2 ratio between high and low RS groups. Data are presented as mean ± 2 s.e.m; 𝑃 value < 0.05 (Mann-Whitney𝑈 test). (b) Relative
expression levels of BAX and BCL-2. Data are presented as mean ± 2 s.e.m. 𝑃one-sided value < 0.05 (Mann-Whitney 𝑈 test). (c) Difference in
active caspase-3 levels between high and low RS groups. Data are presented as mean ± 2 s.e.m; 𝑃one-sided value < 0.05 (Mann-Whitney𝑈 test);
𝑛 = 6 (lower RS); 𝑛 = 5 (higher RS).
better contractility was marked with higher levels of ongoing
apoptosis. These findings correspond to previous observa-
tions that terminal IDCM stage is associated with marked
antiapoptotic response [23]. In agreement with previous data
on end-stage HF [27], we found that a decreased BAX/BCL-
2 ratio in hearts with severely impaired contractility was
mainly due to increased levels of the survival factor Bcl-
2. Moreover, insensitivity to apoptosis was associated with
increased serum adiponectin levels, a predictor for mortality
in patients with chronic HF [28]. Possibly, adiponectin
could account for the reduced BAX/BCL-2 ratio in end-stage
IDCM patients, as it has antiapoptotic effects in myocardium
[29].
Speculatively, stretch-sensing and prosurvival properties
of Ankrd1 could be responsible for the observed antiapoptotic
response in terminal IDCM stages (Figure 5). LV remodeling
in IDCM leading to the wall thickening and chamber dilation
is accompanied by myocyte overstretch and slippage [30]
which in vicious cycle provokes myocyte mechanoptosis
[31]. Subsequently stretchwould directly upregulateANKRD1
transcript and launch Ankrd1-mediated survival cascades.
Hypothetically, ANKRD1 and adiponectin or their agonists
could be used as heart-specific antiapoptotic agents in treat-
ment of IDCM.
This study has some limitations which have to be pointed
out. The study cohort consisted of patients with advanced
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Figure 4: ANKRD1 and adiponectin correlate with tissue propensity to apoptosis. (a) Linear correlation between ANKRD1 expression and
BAX/BCL-2 ratio. Regression line is represented within 95% confidence interval for the mean value. A negative correlation between ANKRD1
expression (−𝐶
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) and BAX/BCL-2 ratio (𝐶
𝑡
) was found (𝑛 = 25, 𝑟 = −0.505, 𝑃 = 0.01). (b) Linear correlation between adiponectin levels and
BAX/BCL-2 ratio. Regression line is represented within 95% confidence interval for the mean value. A negative correlation between serum
adiponectin levels (𝜇g/mL) and cardiac BAX/BCL-2 ratio (𝐶
𝑡
) was observed (𝑛 = 20, 𝑟 = −0.578, 𝑃 < 0.01).
ANKRD1↑ Adiponectin↑NYHA < IV
Apoptosis↓
NYHA IV
?
Overstretch↑
Figure 5: Antiapoptotic response in end-stage IDCM. Speculatively, ongoing apoptosis and myocyte overstretch in vicious cycle mediate the
LV remodeling, whereas myocyte stretch induces Ankrd1 expression and increases adiponectin levels by unknown mechanism that in turn
inhibit apoptotic signaling. Arrows indicate process dynamics in NYHA <IV to NYHA IV transition.
HF (NYHA classes III-IV); thus future research would be
needed to confirm the validity of observed clinical correla-
tions in patients with mild HF (NYHA I-II). Recent studies
have demonstrated that genetic alterations of titin [32] and
ANKRD1 [33, 34] are associated with DCM and result in
poorer prognosis [32]. Thus, it is not excluded that genetic
alterations of titin-ligand networkmight be present in studied
patients. However, observed upregulation ofANKRD1 is very
likely to be universal pathophysiological as it was described
in controlled increased stretch states such as experimental
pressure overload [5] and not due to genetic alterations.
This study was based on patients with advanced stages
of HF (mostly NYHA classes III-IV); thus future research
would be needed to evaluate the validity of observed clinical
correlations in early HF (NYHA I-II).
Although transcript levels do not always represent
changes in protein concentration, our data suggest that
ANKRD1 transcript quantification is sensitive test for mon-
itoring progression of advanced IDCM stages. Moreover,
quantitative RT-PCR might be method of choice to quantify
ANKRD1 levels, when using minute EMB samples.
In conclusion, expression profiling of selectedmechanop-
totic machinery members revealed association between
increased ANKRD1 expression and deterioration of cardiac
contractility and compliance in IDCM patients. Therefore,
elevated ANKRD1 expression could serve as potential clinical
marker to uncover a coming need to plan heart transplanta-
tion in end-stage HF patients. Further research is warranted
on the functional roles of ANKRD1 induction in IDCM
associated apoptosis.
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